The world of life sciences and genomics has experienced a remarkable shift over the past decade, with emerging technologies enabling researchers to identify and analyze novel forms of genetic variation in unprecedented detail. Bionano Genomics (NASDAQ:BNGO) is one such firm leading the charge in this space, with its pioneering Saphyr system offering advanced structural variation detection capabilities.
Investors are noticing the potential inherent in Bionano Genomics’ cutting-edge technologies, as evidenced by Mirae Asset Global Investments Co. Ltd.’s most recent Form 13F filing with the Securities and Exchange Commission (SEC). The company raised its stake in Bionano Genomics by an impressive 28.5% during Q4, increasing its total share ownership to 1,748,342 shares worth $2,553,000. This amounts to approximately 0.59% of the firm’s total shares.
The market eagerly awaits updates on Bionano Genomics’ performance following its March 9th quarterly earnings report. The quarter saw the company post ($0.13) EPS, missing analysts’ consensus estimates by ($0.04). Despite this setback, Bionano Genomics managed to achieve revenue of $8.22 million – slightly underperforming against analyst expectations by just $0.02 million.
Despite concerns about negative returns on equity (53.38%) and net margin (-473.45%), equities analysts remain cautiously optimistic about Bionano Genomics’ prospects for 2021; with predictions that the firm will post -0.4 earnings per share for the current fiscal year.
Bionano Genomics’ positioning within a rapidly developing genomics landscape offers investors a chance to engage actively with some truly innovative technologies, as well as potentially reap significant rewards in market performance returns. Watch this space for further developments within this exciting field!
Bionano Genomics: An Impressive Market Cap and Investment Opportunities in Genome Analysis
Bionano Genomics’ Shares of NASDAQ BNGO opened at $0.65 on Friday, with a 1-year low of $0.60 and a 1-year high of $4.35. The company’s market cap stands at an impressive $199.41 million with a price-to-earnings ratio of -1.38 and a beta of 2.23, while holding over 26% hedge funds and other institutional investors.
The life sciences instrumentation company’s focus is on genome analysis space, where it engages in the development and marketing of the Saphyr system that streamlines cytogenetics by enabling researchers and clinicians to accelerate their search for new diagnostics and therapeutic targets.
CFO Christopher P. Stewart recently acquired 50,000 shares of the firm’s stock at an average cost of $0.67 per share, valued at a total transactional value of $33,500, thereby becoming the possessor of 281,373 shares or approximately 1.20% of the company’s stock.
Several research firms have weighed in on BNGO: BTIG Research dropped their price objective from $3 to $2 while LADENBURG THALM/SH SH reduced their target price from $6 to $4.80 in reports published on May 18th and May 10th respectively; Oppenheimer dropped their price target from $12 to $9 and set an “outperform” rating on the stock in a research report back on February 6th.
Nisa Investment Advisors LLC raised its position in Bionano Genomics by over 146% during Q3 which saw them add an additional amount representing over one-third to their holdings; this brought their total ownership value up to nearly USD 27K while further hedge funds such as Merit Financial Group LLC purchased a new position in Bionano Genomics valuing approximately USD 28K. Metropolitan Life Insurance Co NY raised their position by 46.0% in Q3 with Brinker Capital Investments LLC, purchasing a new position valued at about $41K.
While the firm’s stock has had its highs and lows over the past year, it remains a player within a field of research offering tremendous investment opportunities for those interested in life sciences instrumentations and genome analysis spaces.
Discussion about this post